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A B S T R A C T Studies of live attenuated cytomegalovirus (CMV) vaccine have recently been initiated in man. The possibilities of latent infection and disease resulting from reactivation of vaccine virus are major concerns. Because markers for attenuation of tissue culture-passaged mouse CMV (MCMV) exist, studies of potential adverse effects of vaccination were initiated in mice. Plaque-purified MCMV was passed 12 times in cell culture ("vaccine virus") and shown to be attenuated by virtue of loss of lethality and diminished replication in reticuloendothelial organs of normal mice. Although subcutaneous inoculation of 105 plaqueforming units of wild virus was lethal for mnice immunosuppressed with antilymphocyte serum (18/18 died), "vaccine MCMV" killed only 3/18 (P < 0.05) and was thus shown to be highly attenuated even in immunosuppressed animals. 4 Receive(d for publicationi 22 October 1979 and(l ini revised form 3 December 1979. 798 pressed patients and pregnant women (1-6). These considerations have prompted investigators to develop and study live attenuated cytomegalovirus vaccines. Although preliminary trials have been initiated in normal volunteers (7) (8) (9) (10) and in renal transplant patients (11) , several concerns have arisen regarding the widespread use of such vaccines (12) . First, there are no means of showing that tissue culture-passagedl human cytomegalovirus (CMV)l strains are in fact attenuated because the virus does not infect experimental animals (1). Similar concerns would apply to the possibility of reversion of vaccine CMV to full virulence and subsequent person-to-person spread after passage through the human host. Second, CMV is a member of the herpes group of viruses and, as such, appears to be capable of establishing latent infection in man that may later reactivate and produce disease (1) . The behavior of a "vaccine CMV" strain in this regard is obviously an important consideration.
For the past several years, studies ofthe pathogenesis of experimental and natural CMV infection in mice have yielded important findings that closely mimic human infection (13) (14) (15) (16) (17) (18) . Of relevance to vaccination, Osborne and Walker (19) showed in 1970 that murine CMV (MCMV) was attenuated by serial passage in tissue culture. In addition, loss of lethality for suckling mice and diminished viral replication in the liver and spleen of weanling mice were found to be valuable markers of viral attenuation. Subsequently, vaccinationi of mice with this attenuated virus has been shown to prevent the morbidity and mortality induced by challenge with wild MCMV (19, 20) . Moreover, models of latency and subsequent reactivation of MCMV have also been developed and studied profitably in various laboratories (21) (22) (23) (24) (25) . Thus, many of the issues of concern regarding vaccination of humans with CMV can now be studied experimentally in the murine system. In this report, investigations of the potential adverse effects of vaccination with attenuated MCMV in mice are described with particular emphasis on the development ofvaccine virus latency, subsequent reactivationi, ancl reversion to virulence.
METHODS
.Mfice. Studies To prepare attenuated MCMV for use as a "vaccine virus," single plaques were aspirated wih Pasteur pipettes from terminal virus dilutions in tissue culture plastic trays (Costar, Data Packaginig, Cambridge, Mass.). The virus from these isolated microplaqcues was then reinoculated onto new MEC moniolayers, and the tissue culture fluids were harvested when cv7topathic effects involved 75% of the monolayer. Supernatant virus was then titrated under overlay; the end dilution plaques were isolated a second time. This MCMV clone was used to infect MEC at a multiplicity of infectioni of 1.0, and the resulting virus was repassaged 12 conisecutive times in MEC; one additional plaque purification was done after the eighth passage. The final vaccine virus pool had a titer of 6.4 x 106 PFU/ml. As will be presented subsequently, this virus was shown to be attenuated byvirtue of loss of lethality for suckling mice and diminished replication in the livers and spleens of weanling mice.
Establishmiienit of latenit infection. The techniques and criteria for the establishment oflatent infection with wild-type virulent MICMV have been described in detail elsewhere (24, 25) . Briefly, 4-6-wk-old C3H mice are inoculated subcutaneously with 103 PFU of MCMV, which produces transient replication of virus in the salivary glands. However, by 4 (19) were used. First, lethality of the MCMV strain to be tested for virulence was assessed in 48-72-h-old suckling mice by intraperitoneal inoculation of 1,000 PFU of virus. As will be shown, within 14 d of infectioni mortality rates of 90-100% were found with virulent strains, whereas mortality rates ranged from 0-15% for attenuated strains within this time period. Seconid, some MCMV isolates were selected at random for determination of their ability to replicate in the reticuloendothelial system of mice. Here, 105 PFU of the virus to be tested was inoculated intraperitoneally into 4-wk-old Swiss mice. 7 d later, 10% homogenates of liver and spleen were prepared and titrated for virus content. As noted by Osborne and Walker (19) , virulent MCMV virtually alwvays replicates to titers at least 100-fold higher than attenuated MCMV in these organs. Because the two methods of determination of virulence correlated very closely, lethality in suckling mice was considered the primary criterion although reticuloendothelial replication was use(d as a confirmatory test for randomly selected virus isolates.
Measuremizent of antibody responises in miiice. To determine the titer of circulating antibody against MCCMV in control and infected animals, an indirect im-nmunofluorescenice technique was used as described in detail elsewhere (27) .
Iimutnosuppressiont of mice. For immunosuppression of animals, rabbit antiserumii against murine lymphocytes (ALS), obtained from nMicrobiological Associates, Walkersville, Md., was given intraperitoneally in a dose of 0.3 ml twice weekly. In some experiments, cortisone acetate (Merck Sharpe and Dohme Div., Merck & Co., Inc., West Point, Pa.) was added at a dose of 125 mg/kg i.p. daily. The effects ofthese regimens on peripheral lymphocyte counts, NICMV antibody titers, spleen size, and dissemination of the viral infection have been described (27) .
RESULTS
Attet uatiot of vaccine MIlCMIV. Initial experiments to determine the degree of attenuation of the tissue culture-passaged "vaccine" MCMV are summarized in Table I . The mortality rates caused by challenge of suckling mice with 1,000 PFU of the vaccine strain were far less than those induced by wild virus. Because similar homogenates from uninfected animals were not lethal for suckling mice, this difference was not the result of a toxic effect of salivary gland homogenate in the case of wvild virus. It can also be seen that replication of virus in the liver and spleen of weanling mice was much greater for the wild MCMV straini, correlating closely with the suckling mouse mortality findings.
Serum samples were collected from weanling animals 14 (Table II) . In addition, histologic examination of tissues from animals with reactivating MCMV vaccine infection indicated that virus-specific lesions were present. Characteristic intranuclear inclusions were seen within cytomegalic cells in the liver, lung, spleen, pancreas, kidneys, and salivary glands that were very similar, if not identical, I Numiiber inifected/numlilber tested.
to those seen after reactivation and dissemination of virulent MCMV (27) . In control mice that had never been infected with MCMV, no virus or intranuclear inclusions were noted after immuniosuppression. This finding indicates that the C3H mouse strain used in these experimenits was not naturally infected with latent MCMV before arrival in the laboratory.
From these experiments, it is clear that the vaccine MCMV strain established a latent infection after vaccination, and that reactivation of the vaccine virus occurred during immunosuppression. In addition, tissue lesions consistent with disseminated cytomegalic inclusion disease were found in all animals examined.
Characteristics of reactivatintg vaccine virtns. The vaccine MCMV strains recovered from salivary gland tissue of several animals were characterized in terms of their ability to kill suckling mice and to multiply in the reticuloendothelial system of weanling mice. These data are shown in Table III . It can be seen that both the virulent control MCMV and the attenuated vaccine virus behaved as expected in both suckling and weanling mice. However, the vaccine MCMV strains recovered from immnunosuppressed animals with reactivating latent infection were clearly virulent in suckling mice. In addition, those MCMV strains tested in weanling mice also replicated in the reticuloendothelial system in a manner similar to wild MCMV. Thus, the vaccine MCMV strains recovered from salivary gland tissue of mice after reactivation of latent infection had reverted to full virulence.
These data do not allow determination as to whether vaccine MCMV reverted to virulence before or after establishment of latent infection. To answer this question, virus recovered from salivary gland homogenates prepared 2 wk after initial inoculation of vaccine MCMV into mice was tested for virulence markers. Data presented in Table IV show that MCMV obtained from aniimals during this acute stage ofthe infection had reverted to virulence as measured both in suckling and weanling mice before development of latency. Thus, establishment of latent infection was clearly not required for reversion of vaccine virus to virulence.
DISCUSSION
From these experiments in the murine inodel, it is apparent that the vaccine MCMV strain was highly attenuated at the time of inoculation of animals. As expected (19) , this virus was not lethal for suckling mice and replicated poorly in the reticuloendothelial system 3 11/12 (92) 6 .0 x 106 7.4 x 104 4 13/14 (93) of weanling mice. In addition, a relatively large challenge dose (105 PFU) of the vaccine virus failed to kill weanling animals immunosuppressed with ALS. The magnitude of these differences from wild-type control virus was significant and consistently demonstrable.
4 mo after vaccination, no infectious virus was detectable in the tissues of normal mice. However, immunosuppression produced reactivation and dissemination of the vaccine virus in virtually all animals, and histologic evidence of widespread cytomegalic inclusion disease was found. In this respect, the vaccine MCMV behaved in a fashion identical to wild-type virulent MCMV, which can be consistently activated from a latent state by immunosuppression (22, (24) (25) (26) (27) . Indeed, characterization of the reactivating vaccine virus recovered from salivary glands clearly indicated that reversion to virulence had occurred. Previous studies of acute infections in mice by Osborne and Walker (19) showed that attenuation of MCMV was an unstable characteristic. A single back passage of attenuated virus in mice resulted in return of virulence, at least as measured by virus multiplication in weanling animals. The data presented here confirm and extend these findings to include corroborative lethality studies in suckling mice. In addition, characterization ofthe vaccine virus shortly after inoculation indicated that reversion to virulence occurred early, during the acute stage of infection. Thus, the virus that established latent infection was already virulent and, not surprisingly, remained so during the reactivation process. This observation sheds light on the events involved in the establishment of latency by vaccine virus and indicates that reversion was not directly related to viral latency. However, from the standpoint of potential adverse effects of a CMV vaccine, the implications of those findings are the same whether reversion occurred before or after latent infection was established.
The relevance of these results to human CMV vaccination is not yet known. Because the murine model can be manipulated experimentally, important fundamental features of the pathogenesis of acute, chronic, and, more recently, latent infection have been elucidated. In all important respects, the findings have substantiated our concepts of the virus-host interactions that are thought to occur in man. Because distinct markers for attenuation ofthe mouse virus exist (19) , and protection against wild-virus challenge has been demonstrated (19, 20) , the system is suitable for investigations of both the beneficial and potential adverse effects of CMV vaccination. However, the fact remains that MCMV is a different virus from the human CMV strains. It is conceivable that repeated cell-culture passage serves to attenuate human CMV in a more stable manner than with MCMV, and that reversion to virulence may not occur as readily in man after vaccination. In this regard, the lack of a suitable marker to determine the virulence status of the human CMV vaccine strains is a major drawback.
To date, significant systemic adverse reactions to vaccination with cell-culture passaged CMV have not been noted in man (7) (8) (9) (10) . Both humoral and cellmediated virus-specific immune responses have been demonstrated in vaccinated patients (11) . Whether the vaccine will be effective in preventing or modifying CMV infections, particularly in immunocompromised patients, remains to be determined. In preliminary trials of CMV vaccination in renal transplant recipients, six of nine vaccinated patients subsequently excreted CMV in the urine, but restriction endonuclease analyses of the DNA of recovered viruses were different from the vaccine strain (11) . Studies with the murine model indicate that the cautious selection of vaccinated patients and the rigorous clinical and virologic surveillance employed to date are clearly warranted in studies of the safety and efficacy of human CMV vaccine.
